Portfolio

We take a back-and-build approach to our investments, helping entrepreneurs access the human, intellectual, and financial resources needed to go the distance.

RNA targeting platform focused on genetic, cardiometabolic and central nervous system diseases

Whole-gene insertion technologies to enable a potential new class of genetic medicines

Innovative gene-based immuno-oncology treatments for solid tumors

Clinical stage company focused on developing therapies for viral diseases

Clinical stage company developing next generation TYK2 inhibitors for autoimmune diseases

Clinical stage biologic treatments for oncology and inflammatory diseases

A clinical-stage Danish biotech focused on targeting the Glucose-Dependent Insulinotropic Polypeptide (GIP) receptor to pioneer novel treatments for obesity and cardiometabolic diseases.

Novel, adaptive, controllable cell therapies for the treatment of patients with cancer and autoimmune diseases

Developing an easy-to-use and needle-free epinephrine nasal spray to treat severe allergies

Novel, oral small molecule therapeutics for neurodegenerative diseases

Clinical stage company developing inhaled therapies to treat rare respiratory diseases

Clinical stage company advancing a pipeline of potential best-in-class oncology therapies

A new class of small, chemically synthesized medicines for oncology and beyond

Clinical-stage company leveraging Targeted Protein Degradation for novel therapeutics for oncology and inflammatory diseases

Discovery stage biotech developing therapeutics exploiting alternative RNA splicing.

Transformative gene-based medicines for serious human diseases

Groundbreaking treatments to restore and improve hearing and balance

New class of molecules for degenerative disorders

Platform for selective depletion of disease-causing cells in oncology and other diseases

Discovery stage company targeting extrachromosomal DNA to power the next wave of cancer treatments.

Clinical stage oncology company pioneering a class of selective translation regulators

Formulation technology making biologic therapies more accessible

Highly selective medicines for functionally and genomically defined cancer patients

Unlocking nature's regulatory mechanisms to fuel the discovery of new medicines

Novel treatments for Tauopathies

Developing therapies for rare ocular surface and retinal diseases

Clinical stage company developing a MDM2 inhibitor- Navtemadlin- for the treatment of myelofibrosis

Clinical stage company developing a candidate for a targeted approach to hypertension

Advanced therapeutics for patients suffering from a range of autoimmune diseases

Targeting the ubiquitin pathway with a new class of drugs

A new generation of oral integrin therapies for the treatment of serious chronic diseases

Pioneering technologically-driven methods of drug discovery, to make therapeutics against the most challenging of targets

Improving upon the efficacy of cell therapy, making it more rapidly available to the broad population

A high-throughput proteomics platform to enable drug discovery

Focused on transforming lives of patients with immune dysfunctions and cancer

Extended half-life biologic treatments for psoriasis and other inflammatory diseases.

Glyco-sensing molecules designed to overcome resistance to first-generation immuno-oncology drugs

Therapeutics for localized immunomodulation at the site of disease for patients with autoimmune and inflammatory disease

Phylaxis BiosciencesNext-generation IgE targeting biologics for the treatment of food allergy and other allergic diseases.

Oral treatments for immune diseases

Taking a smarter approach to fertility and family building benefit solutions

Advanced inhaled anti-infectives for targeted treatment of life-threatening lung infections

Clinical stage company developing innovative therapeutics for renal diseases for Japanese and Asian patients

Pioneering the integrated mapping of disease networks for precision therapeutics

River RenalClinical stage company focused on orphan renal diseases

Biologic to treat the thyroid eye disease

Clinical stage company developing a novel IL-18 construct to treat oncology patients

Focused on identifying, developing and commercializing medicines for multi-drug resistant (MDR) bacterial infections and rare disease

Clinical stage company developing a novel targeted therapy to treat selected blood cancers and ophthalmology diseases

Discovering innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases

Develop novel therapeutics for complement-mediated rare diseases

Targeted cancer therapies designed to address treatment resistance and improve lives

Developing vaccines for infectious diseases of high unmet medical need

Early stage company from the founders of CRISPR Therapeutics

Clinical- stage biopharmaceutical company whose ambition is to become a leader in the development and commercialization of inflammation and immunology (I&I) directed therapies

NOTE: Referenced portfolio companies are provided for illustrative purposes only and this list may not be comprehensive, and it should not be assumed that any referenced portfolio companies were or will be profitable. Certain of these investments were made by the SR One team while part of the legacy business with GSK and are not in the Fund I or Fund II portfolios. Past performance is not a guarantee of future results. The views expressed on this website (a) are strictly those of SR One, (b) are for informational purposes only, (c) are not intended to provide a basis for evaluating any investment acquisition or disposition, (d) are not a recommendation of any particular investment or security, and (e) are not a recommendation to invest in any particular fund advised or managed by SR One.